Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearItem 5.03.
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
As previously announced, effective as of November 7, 2017, Sun BioPharma, Inc. (the “Company”) amended its Certificate of Incorporation to effect a reverse split of the Company’s common stock at a ratio of one-for-ten (1:10) and reduce the shares authorized for issuance by 50%. The amendments, including the reverse split, were previously approved by the Company’s stockholders as set forth in the definitive consent solicitation statement on Schedule 14A filed with the Securities and Exchange Commission on August 22, 2017.
On November 8, 2017, the Company restated its Certificate of Incorporation (the “Restated Certificate”) to integrate all prior amendments. The Restated Certificate did not revise any provision of the Company’s Certificate of Incorporation. The text of the Restated Certificate is attached as Exhibit 3.1.
|
Item 9.0 |
Financial Statements and Exhibits. |
(d)Exhibits
Sun BioPharma, Inc. ExhibitEX-3.1 2 ex_100592.htm EXHIBIT 3.1 ex_100592.htm Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF SUN BIOPHARMA,…To view the full exhibit click here
About Sun BioPharma, Inc. (OTCMKTS:SNBP)
Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company’s products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer.
